Mentype® AMLplexQS

Mentype®AMLplexQS represents the ideal screening tool to detect gene aberrations associated with acute myeloid leukaemia (AML). One reaction of this multiplex-PCR application provides analysis of 11 gene-fusions, and in total 34 transcript variants. RNA isolated from blood or bone-marrow should be transcribed to cDNA and, subsequently, can be transferred to the kit's optimised components for multiplex analysis. Primers are fluorescence-labeled with 6-FAMTM, BTG, or BTY allowing a fast and sensitive analysis by capillary electrophoresis.

Gene fusion

Aberration

Variants

AML1-ETO

t(8;21)(q22;q22)

-

BCR-ABL

t(9;22)(q34;q11)

e1a2/3, b2a2/3, b3a2/3

CALM-AF10

t(10;11)(p13;q14)

AF10_240-CALM_1987

AF10_240-CALM2092

CBFB-MYH11

inv(16)(p13;q22)

Typ A, B, C, D, E, F, G, H, I, J

DEK-CAN

t(6;9)(p23;q34)

-

MLL-AF6

t(6;11)(q27;q23)

-

MLL-AF9

t(9;11)(p22;q23)

6A_(THP1), 7A_(10A),

8A_(MM6), 6B_(9B)

MLL-ELL

t(11;19)(q23;p13.1)

e10e2/3

MLL-PTD

part. tandem duplication

e9e3, e10e3, e11e3

NPM1-MLF1

t(3;5)(q25.1;q34)

-

PML-RARA

t(15;17)(q22;q21)

bcr1 (PR-L), bcr2 (PR-V),

bcr3 (PR-S)

The amount of isolated RNA and quality of the reverse transcription reaction is displayed by the enclosed ABL-control. Successful multiplex amplification is monitored by a control-amplification of the internal quality sensor “QS”. Furthermore, a cDNA carrying the AML1-ETO translocation is enclosed as a positive control.